Selected research
Industry Research
Recombinant Insulin Glargine Industry Research Report 2026
Market perspective
The global Recombinant Insulin Glargine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Recombinant Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Recombinant Insulin Glargine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Recombinant Insulin Glargine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Recombinant Insulin Glargine include United Laboratories, Tonghua Dongbao, Sanofi, Eli Lilly & Co, Gan & Lee, Wockhardt, Viatris, Swixx Biopharma and Lupin Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Recombinant Insulin Glargine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Insulin Glargine Market by Company
United Laboratories
Tonghua Dongbao
Sanofi
Eli Lilly & Co
Gan & Lee
Wockhardt
Viatris
Swixx Biopharma
Lupin Laboratories
KALBE PHARMA
INFION PHARMA
Cipla
Biocon Biologics
Biocare
Recombinant Insulin Glargine Segment by Type
Vial
Prefilled
Recombinant Insulin Glargine Segment by Application
Type 1 Diabetes
Type 2 Diabetes
Recombinant Insulin Glargine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Insulin Glargine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Insulin Glargine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Insulin Glargine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Recombinant Insulin Glargine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Recombinant Insulin Glargine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Recombinant Insulin Glargine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vial
- Prefilled
Applications
- Type 1 Diabetes
- Type 2 Diabetes
Companies covered
- United Laboratories
- Tonghua Dongbao
- Sanofi
- Eli Lilly & Co
- Gan & Lee
- Wockhardt
- Viatris
- Swixx Biopharma
- Lupin Laboratories
- KALBE PHARMA
- INFION PHARMA
- Cipla
- Biocon Biologics
- Biocare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Recombinant Insulin Glargine Market Size (2021-2032)
- 2.2.2 Global Recombinant Insulin Glargine Sales (2021-2032)
- 2.2.3 Global Recombinant Insulin Glargine Market Average Price (2021-2032)
- 2.3 Recombinant Insulin Glargine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Vial
- 2.3.3 Prefilled
- 2.4 Recombinant Insulin Glargine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Type 1 Diabetes
- 2.4.3 Type 2 Diabetes
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Recombinant Insulin Glargine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Recombinant Insulin Glargine Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Recombinant Insulin Glargine Revenue of Manufacturers (2021-2026)
- 3.4 Global Recombinant Insulin Glargine Average Price by Manufacturers (2021-2026)
- 3.5 Global Recombinant Insulin Glargine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Recombinant Insulin Glargine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Recombinant Insulin Glargine, Product Type & Application
- 3.8 Global Manufacturers of Recombinant Insulin Glargine, Established Date
- 3.9 Global Recombinant Insulin Glargine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 United Laboratories
- 4.1.1 United Laboratories Company Information
- 4.1.2 United Laboratories Business Overview
- 4.1.3 United Laboratories Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 United Laboratories Recombinant Insulin Glargine Product Portfolio
- 4.1.5 United Laboratories Recent Developments
- 4.2 Tonghua Dongbao
- 4.2.1 Tonghua Dongbao Company Information
- 4.2.2 Tonghua Dongbao Business Overview
- 4.2.3 Tonghua Dongbao Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Tonghua Dongbao Recombinant Insulin Glargine Product Portfolio
- 4.2.5 Tonghua Dongbao Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Recombinant Insulin Glargine Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Eli Lilly & Co
- 4.4.1 Eli Lilly & Co Company Information
- 4.4.2 Eli Lilly & Co Business Overview
- 4.4.3 Eli Lilly & Co Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Eli Lilly & Co Recombinant Insulin Glargine Product Portfolio
- 4.4.5 Eli Lilly & Co Recent Developments
- 4.5 Gan & Lee
- 4.5.1 Gan & Lee Company Information
- 4.5.2 Gan & Lee Business Overview
- 4.5.3 Gan & Lee Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Gan & Lee Recombinant Insulin Glargine Product Portfolio
- 4.5.5 Gan & Lee Recent Developments
- 4.6 Wockhardt
- 4.6.1 Wockhardt Company Information
- 4.6.2 Wockhardt Business Overview
- 4.6.3 Wockhardt Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Wockhardt Recombinant Insulin Glargine Product Portfolio
- 4.6.5 Wockhardt Recent Developments
- 4.7 Viatris
- 4.7.1 Viatris Company Information
- 4.7.2 Viatris Business Overview
- 4.7.3 Viatris Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Viatris Recombinant Insulin Glargine Product Portfolio
- 4.7.5 Viatris Recent Developments
- 4.8 Swixx Biopharma
- 4.8.1 Swixx Biopharma Company Information
- 4.8.2 Swixx Biopharma Business Overview
- 4.8.3 Swixx Biopharma Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Swixx Biopharma Recombinant Insulin Glargine Product Portfolio
- 4.8.5 Swixx Biopharma Recent Developments
- 4.9 Lupin Laboratories
- 4.9.1 Lupin Laboratories Company Information
- 4.9.2 Lupin Laboratories Business Overview
- 4.9.3 Lupin Laboratories Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Lupin Laboratories Recombinant Insulin Glargine Product Portfolio
- 4.9.5 Lupin Laboratories Recent Developments
- 4.10 KALBE PHARMA
- 4.10.1 KALBE PHARMA Company Information
- 4.10.2 KALBE PHARMA Business Overview
- 4.10.3 KALBE PHARMA Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 KALBE PHARMA Recombinant Insulin Glargine Product Portfolio
- 4.10.5 KALBE PHARMA Recent Developments
- 4.11 INFION PHARMA
- 4.11.1 INFION PHARMA Company Information
- 4.11.2 INFION PHARMA Business Overview
- 4.11.3 INFION PHARMA Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 INFION PHARMA Recombinant Insulin Glargine Product Portfolio
- 4.11.5 INFION PHARMA Recent Developments
- 4.12 Cipla
- 4.12.1 Cipla Company Information
- 4.12.2 Cipla Business Overview
- 4.12.3 Cipla Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Cipla Recombinant Insulin Glargine Product Portfolio
- 4.12.5 Cipla Recent Developments
- 4.13 Biocon Biologics
- 4.13.1 Biocon Biologics Company Information
- 4.13.2 Biocon Biologics Business Overview
- 4.13.3 Biocon Biologics Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Biocon Biologics Recombinant Insulin Glargine Product Portfolio
- 4.13.5 Biocon Biologics Recent Developments
- 4.14 Biocare
- 4.14.1 Biocare Company Information
- 4.14.2 Biocare Business Overview
- 4.14.3 Biocare Recombinant Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Biocare Recombinant Insulin Glargine Product Portfolio
- 4.14.5 Biocare Recent Developments
5 Global Recombinant Insulin Glargine Market Scenario by Region
- 5.1 Global Recombinant Insulin Glargine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Recombinant Insulin Glargine Sales by Region: 2021-2032
- 5.2.1 Global Recombinant Insulin Glargine Sales by Region: 2021-2026
- 5.2.2 Global Recombinant Insulin Glargine Sales by Region: 2027-2032
- 5.3 Global Recombinant Insulin Glargine Revenue by Region: 2021-2032
- 5.3.1 Global Recombinant Insulin Glargine Revenue by Region: 2021-2026
- 5.3.2 Global Recombinant Insulin Glargine Revenue by Region: 2027-2032
- 5.4 North America Recombinant Insulin Glargine Market Facts & Figures by Country
- 5.4.1 North America Recombinant Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Recombinant Insulin Glargine Sales by Country (2021-2032)
- 5.4.3 North America Recombinant Insulin Glargine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Recombinant Insulin Glargine Market Facts & Figures by Country
- 5.5.1 Europe Recombinant Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Recombinant Insulin Glargine Sales by Country (2021-2032)
- 5.5.3 Europe Recombinant Insulin Glargine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Recombinant Insulin Glargine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Recombinant Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Recombinant Insulin Glargine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Recombinant Insulin Glargine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Recombinant Insulin Glargine Market Facts & Figures by Country
- 5.7.1 South America Recombinant Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Recombinant Insulin Glargine Sales by Country (2021-2032)
- 5.7.3 South America Recombinant Insulin Glargine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Recombinant Insulin Glargine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Recombinant Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Recombinant Insulin Glargine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Recombinant Insulin Glargine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Recombinant Insulin Glargine Sales by Type (2021-2032)
- 6.1.1 Global Recombinant Insulin Glargine Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Recombinant Insulin Glargine Sales Market Share by Type (2021-2032)
- 6.2 Global Recombinant Insulin Glargine Revenue by Type (2021-2032)
- 6.2.1 Global Recombinant Insulin Glargine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Recombinant Insulin Glargine Revenue Market Share by Type (2021-2032)
- 6.3 Global Recombinant Insulin Glargine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Recombinant Insulin Glargine Sales by Application (2021-2032)
- 7.1.1 Global Recombinant Insulin Glargine Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Recombinant Insulin Glargine Sales Market Share by Application (2021-2032)
- 7.2 Global Recombinant Insulin Glargine Revenue by Application (2021-2032)
- 7.2.1 Global Recombinant Insulin Glargine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Recombinant Insulin Glargine Revenue Market Share by Application (2021-2032)
- 7.3 Global Recombinant Insulin Glargine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Recombinant Insulin Glargine Value Chain Analysis
- 8.1.1 Recombinant Insulin Glargine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Recombinant Insulin Glargine Production Mode & Process
- 8.2 Recombinant Insulin Glargine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Recombinant Insulin Glargine Distributors
- 8.2.3 Recombinant Insulin Glargine Customers
9 Global Recombinant Insulin Glargine Analyzing Market Dynamics
- 9.1 Recombinant Insulin Glargine Industry Trends
- 9.2 Recombinant Insulin Glargine Industry Drivers
- 9.3 Recombinant Insulin Glargine Industry Opportunities and Challenges
- 9.4 Recombinant Insulin Glargine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst